Zymeworks finalized its acquisition of Theravance Biopharma, providing updated 2026 financial guidance including revenue and adjusted EBITDA projections. This deal is expected to generate immediate recurring cash flow and expand operating leverage through the addition of YUPELRI, a key revenue driver.
Zymeworks' 8-K filing details the finalization of its acquisition of Theravance Biopharma, a significant strategic move. The updated 2026 financial guidance, projecting $278M-$292M in revenue and $114M-$128M in adjusted EBITDA, provides clear forward-looking metrics for investors. The acquisition of YUPELRI, which generated $133.1M in sales in H1 2026 and is expected to drive a mid-teens internal rate of return, is a key growth driver. The use of $600M in non-dilutive financing for the purchase and share repurchases, coupled with no plans for additional equity offerings, signals a strong financial structure and commitment to minimizing shareholder dilution. This event is a positive catalyst for Zymeworks, indicating a clear path to increased revenue and profitability, and potentially attracting new investors.